AstraZeneca resuming US testing of COVID-19 vaccine

AstraZeneca Inc. anunced Friday that regulators are letting it resume testing of its COVID-19 vaccine candidate in U.S.

Testing of vaccine was halted worldwide early last month because of a British study volunteer’s illness. Studies have alrey resumed in or countries, and British drugmaker said Food and Drug ministration gave company go-ahe Friday to resume U.S. testing.

AstraZenca vaccine, developed with Oxford University, is one of several coronavirus vaccine candidates in final-st testing around world.

drugmaker said it was allowed to resume testing after FDA “reviewed all safety data from trials globally and concluded it was safe to resume trial.”

company said that testing has alrey resumed in United Kingdom, Brazil, South Africa and Japan.

Such temporary halts of drug and vaccine testing are relatively common, because in research involving thousands of participants, some are likely to fall ill. Putting a study on hold allows researchers to investigate wher an illness is a side effect or a coincidence.

AstraZeneca's study in U.S. involves 30,000 people, with some getting vaccine and ors a dummy shot.

Testing was stopped after one participant in United Kingdom developed severe neurological symptoms consistent with a rare inflammation of spinal cord called transverse myelitis. It was second hold in AstraZeneca testing.

This story has t been edited by www.republicworld.com and is auto-generated from a syndicated feed.